Actively Recruiting
Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-01-07
58
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Breast cancer is the most common malignancy in women worldwide. Patients with breast cancer are often diagnosed at later stages and have a strong desire for breast conservation, necessitating neoadjuvant chemotherapy. Tumors of different molecular subtypes and individual variations among patients lead to significant differences in treatment efficacy. Precise assessment of patients' responses to treatment regimens is imperative in advancing prognosis of breast cancer. In this study, 58 patients diagnosed with breast cancer and scheduled for neoadjuvant therapy will be recruited. Patient-derived organoids from their tumor biopsies will be utilized to evaluate the sensitivity of chemotherapy regimen. These drugs primarily include Doxorubicin, Carboplatin, Cyclophosphamide, Paclitaxel, as well as targeted therapies such as Herceptin and Pertuzumab.
CONDITIONS
Official Title
Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form and willingness to participate in the clinical study.
- Female patients aged between 18 and 70 years old.
- Confirmed early-stage breast cancer eligible for surgery (AJCC stages I to IIIA), with a tumor diameter of 2cm or more detected by MRI and no distant metastasis (M0).
- If multiple lesions are present, the largest lesion must have a diameter of 2cm or more.
- ECOG performance status score of 0-1.
- No significant abnormalities in liver and kidney function (bilirubin <1.5 times upper limit of normal; ALT and AST <2.5 times upper limit of normal; creatinine 2 times upper limit of normal).
You will not qualify if you...
- Received prior treatments.
- Locally advanced breast cancer not suitable for surgery or inflammatory breast cancer (unresectable AJCC stage III).
- Bilateral breast cancer.
- Multiple breast cancers in different quadrants.
- Not suitable for neoadjuvant chemotherapy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
Z
ZHIGANG CHEN
CONTACT
J
Jian Huang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here